WGS Q4 2024 Earnings — GeneDx Holdings Corp. Revenue & Financial Results | Market Cap Arena

WGSGeneDx Holdings Corp.

$3B

Q4 2024 Earnings

Healthcare Medical - Healthcare Information Services

Income Statement

Revenue

$96M+66.6% YoY

Gross Profit

$66M69.2% margin

Operating Income

$9M9.2% margin

Net Income

$5M5.7% margin

EPS (Diluted)

$0.20

QoQ Revenue Growth

+24.4%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$6M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$419M

Total Liabilities

$174M

Stockholders' Equity

$245M

Cash & Equivalents

$85M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$96M	$57M	+66.6%
Gross Profit	$66M	$31M	+115.3%
Operating Income	$9M	-$26M	+134.3%
Net Income	$5M	-$26M	+121.1%

Revenue Segments

Diagnostic Test

$155M50%

Diagnostic Test, Third Party Insurance

$123M39%

Diagnostic Test, Institutional Customers

$31M10%

Product and Service, Other

$3M1%

Diagnostic Test, Self Pay

$1M0%